Giroctocogene fitelparvovec

菲格可基

Report date: 2026/05/20 20:02:01

Base Information

Drug NameGiroctocogene fitelparvovec

Drug Alias Name第八因子基因疗法Recombinant AAV2/6 Human Factor 8 Gene Therapy - Sangamo Therapeutics八因子基因疗法Giroctocogene fitelparvovec - Pfizer/ Sangamo TherapeuticsAAV cDNA gene therapy - Sangamo Therapeutics +[12]

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2/6 vector

Mechanisms of ActionBlood coagulation pathway activationCoagulation factor VIII modulatorsFactor VIII gene transference

TargetsCoagulation factor VIII

Therapy Area/IndicationsHemophilia A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSweden +[15]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesSangamo Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc

Inactive CompaniesN/A

Active IndicationsHemophilia A

Inactive IndicationsN/A

Other Information

ATC CodeN/A